Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ER degradation enhancer, mannosidase alpha-like 1 pseudogene (ENSG00000228480) is annotated as a *pseudogene* related to the functional gene *EDEM1* (ER degradation-enhancing alpha-mannosidase-like protein 1)[3]. Pseudogenes are genomic sequences similar to known genes but do not encode functional proteins due to mutations such as frameshifts or premature stop codons[7]. Recent research indicates some pseudogenes can play regulatory roles at the RNA level, such as acting as microRNA decoys or generating small RNAs, potentially modulating the expression of their parent or related genes[5][7]. However, there is no direct evidence that this specific pseudogene is involved in protein coding, therapeutic targeting, or well-characterized disease pathways. In summary, ENSG00000228480 is not a protein-coding gene or validated therapeutic target, but a pseudogene, and should not be considered a canonical receptor, enzyme, or other druggable molecular entity at this time[3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ER degradation enhancer, mannosidase alpha-like 1 pseudogene (ENSG00000228480).